Join to learn more about a closed-loop supply chain in healthcare.
Personalized treatments, like autologous cell therapies, are based on a concept that involves a single patient’s input, either in form of physical raw material (e.g. blood or tissue cells) or of data based on the patient’s analysis to produce a medicine specifically for this patient. A promising approach to reduce costs and production times of personalized cell & gene therapies is the point-of-care production model. It excludes the need to freeze and thaw the materials as well as the need to transport at all.
Cell&Gene Therapies have the power to irretrievably transform today’s research and care models and hold great potential within the field of healthcare.
Jeroen Voorham, CellPoint
Marten Neubauer, Healthcare Field Director, Germany, Dell Technologies
Andreas Göbel, Managing Director, Hypertrust Patient Data Care